Search research articles
Contact Us
Filters
Showing results (91-100 of 133) with videos related to
Page
of 14
Sort By:
Leukemia & Lymphoma
|
October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†
Tony Reiman, Kerry J Savage, Michael Crump, et al.
Blood Advances
|
August 23, 2019
Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis
Elina K Cook, Terumi Izukawa, Sherylan Young, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Leukemia & Lymphoma
|
January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 21, 2003
Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy
Kojo S J Elenitoba-Johnson, Stephen D Jenson, Robert T Abbott, et al.
American Journal of Hematology
|
December 21, 2023
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies
Rena Buckstein, Jeannie Callum, Anca Prica, et al.
Iscience
|
September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
Nathan Radakovich, David A Sallman, Rena Buckstein, et al.
Blood Cancer Journal
|
April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Amer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Hepatology Communications
|
December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial
Sanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 133) with videos related to
Sort By:
Page
of 14
Leukemia & Lymphoma
|
October 11, 2018
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†
Tony Reiman, Kerry J Savage, Michael Crump, et al.
Blood Advances
|
August 23, 2019
Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis
Elina K Cook, Terumi Izukawa, Sherylan Young, et al.
British Journal of Haematology
|
June 17, 2025
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, et al.
Leukemia & Lymphoma
|
January 6, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Rena Buckstein, Lisa Chodirker, Karen W L Yee, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 21, 2003
Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy
Kojo S J Elenitoba-Johnson, Stephen D Jenson, Robert T Abbott, et al.
American Journal of Hematology
|
December 21, 2023
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies
Rena Buckstein, Jeannie Callum, Anca Prica, et al.
Iscience
|
September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
Nathan Radakovich, David A Sallman, Rena Buckstein, et al.
Blood Cancer Journal
|
April 7, 2026
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Amer M Zeidan, Valeria Santini, María Díez-Campelo, et al.
Hepatology Communications
|
December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial
Sanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Page
of 14